All Updates

All Updates

icon
Filter
M&A
Iterative Scopes acquires two clinical trial optimization companies to support IBD drug development process
AI Drug Discovery
Apr 28, 2022
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
AI Drug Discovery

AI Drug Discovery

Apr 28, 2022

Iterative Scopes acquires two clinical trial optimization companies to support IBD drug development process

M&A

  • Bioinformatics startup Iterative Scopes has acquired two clinical trial optimization companies, Clinical Research Strategy Group and Precision Research, to support the drug development process for inflammatory bowel disease (IBD). The acquisition is part of its plans to strengthen ties with the IBD clinical research community and research sites.

  • Iterative Scopes uses AI-powered computational algorithms to help patients find new treatments faster and help pharmaceutical companies expedite their IBD clinical trials process. The acquisition will help enhance the firm’s knowledge of the research process and accelerate drug development as both clinical trial companies work with a network of clinical research sites and community gastroenterologists across the US, with a focus on optimizing clinical trials for IBD treatments.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.